NOVARTIS CROP DISEASE DIAGNOSTICS
JJ BECK1, SJ STEWART2, L ETIENNE3, C BASSIN3, C THOMAS4, SJE WEST4, A ABEL5, E SCHURMANN5, P OROSZLAN5, M EHRAT5 and U GISI3
1Novartis Crop Protection, Biotechnology and Genomics Center, 3054 Cornwallis Road, Research Triangle Park, North Carolina 27709 USA; 2Immunovation, PO Box 13342, Research Triangle Park, North Carolina 27709 USA; 3Novartis Crop Protection Ltd, Agrobiology Research Station, CH-4108 Witterswil, Switzerland; 4Novartis Crop Protection UK Ltd, Whittlesford, Cambridge CB2 4QT, UK; 5Novartis Pharma Ltd, BioAnalytical Research, CH-4002 Basel, Switzerland
Background and objectives
All our assays are pre-symptomatic in detection, that is they identify the presence of the pathogen before the onset of visible disease symptoms. In addition, these assays provide a tool for identifying the diseases without the problems of traditional disease diagnosis and the isolation of the pathogen. Novartis diagnostics is an ongoing program to support our customers' needs with the applicable solutions.
Results and conclusions
We have also developed diagnostic assays using polymerase chain reaction (PCR) technology. By targeting a pathogen-specific gene, highly specific PCR primers have been developed which amplify DNA only from the targeted pathogen. These assays are highly sensitive, inexpensive to develop and are very specific. As with our onsite assays, the PCR results correlate well with our existing ELISA assays.
PCR tests are performed pursuant to licensing arrangements with the Perkin-Elmer Corporation under patent rights owned by F. Hoffman-LaRoche Limited and Hoffman LaRoche Incorporated.